摘要
CDK4/6抑制剂(CDK4/6 inhibitors,CDK4/6i)通过调控Rb/E2F通路,诱导细胞周期停滞,抑制细胞增殖,发挥抗肿瘤作用,被FDA批准用于乳腺癌的治疗,并在多个瘤种中被广泛研究。在消化道肿瘤相关研究中,CDK4/6i表现出较好的抗肿瘤活性,并可与化疗、靶向治疗、免疫治疗和放疗等产生良好的协同效果。全文现就CDK4/6i近年在消化道肿瘤的研究进展作一综述。
CDK4/6inhibitors(CDK4/6i)can arrest the cell cycle and inhibit cell proliferation through regulating the Rb/E2F pathway,which have been approved by FDA for treatment of breast cancer and also widely studied in other tumor types.In gastrointestinal cancer,CDK4/6i has shown excellent antitumor activity with optimal synergistic effect with chemotherapy,target therapy,immunotherapy and radiotherapy.This article reviews the progress on CDK4/6i for treatment of gastrointestinal cancer.
作者
聂建华
李顺
张书源
林彬琳
张纯慧
郑桐森
NIE Jian-hua;LI Shun;ZHANG Shu-yuan;LIN Bin-lin;ZHANG Chun-hui;ZHENG Tong-sen(Harbin Medical University Cancer Hospital,Harbin 150081,China)
出处
《肿瘤学杂志》
CAS
2021年第10期805-812,共8页
Journal of Chinese Oncology
基金
国家自然科学基金(81872435,81672930)。
